UNIVERSITY OF MICHIGAN

The META-AF study found that 78% of overweight/obese adults with atrial fibrillation who took metformin after catheter ablation remained free from AFib episodes for one year, compared to 58% in the usual care group.

A meta-analysis of six prospective controlled studies involving 3,532 adults with major depressive disorder showed that GeneSight test-guided treatment resulted in 41% higher remission rates and 30% higher response rates compared to treatment as usual.

Researchers at University of Virginia and University of Michigan developed a humanized monoclonal antibody targeting citrullinated histone H3 to combat sepsis, which kills approximately 11 million people worldwide annually.

Researchers at the University of Michigan have developed the ExoPatch, a silicone patch with star-shaped microneedles that can detect melanoma by capturing disease-specific exosomes from skin tissue.

Biomerica has appointed Scott Madel as Chief Commercial Officer to accelerate commercialization of its inFoods IBS diagnostic test, bringing over 20 years of experience in laboratory testing and clinical diagnostics.

Courage Therapeutics has appointed biopharma veteran Giovanni Ferrara as CEO following a significant investment from Arsenal Bridge Ventures in May.

Epcoritamab-bysp achieved durable complete responses in patients with relapsed/refractory large B-cell lymphoma, with 96% of complete responders at 2 years maintaining remission at 3 years.

Mayo Clinic researchers identified that mineralocorticoid receptor proteins clump together during cold storage, causing cardiac damage through increased inflammation and cell death.

• University of Michigan researchers have demonstrated that DT-109, a glycine-based tripeptide, significantly reduces atherosclerotic plaque formation in nonhuman primates while inhibiting vascular calcification processes. • The compound, which previously showed efficacy in treating metabolic dysfunction-associated steatotic liver disease (MASH), represents a potential breakthrough as a dual-action therapy addressing both liver dysfunction and cardiovascular complications. • Unlike conventional treatments that primarily lower cholesterol, DT-109 targets underlying inflammatory pathways including NLRP3 inflammasome signaling, potentially addressing root causes of atherosclerosis rather than just managing symptoms.

Breakthrough T1D has awarded $2.8 million over three years to create the U-M-OHSU Cardiorenal Center of Excellence, expanding research on heart and kidney complications in type 1 diabetes patients.